Table 3. Methylation of NRG1 exon 1 in invasive carcinomas (IC), morphologically normal tissue adjacent to IC and normal human breast tissues.
Patient number | Age | Diagnostic | NRG1 |
---|---|---|---|
Group 1: Control Group (normal tissue adjacent to benign lesions) | |||
148115 | 60 | Bening breast disease | U |
135447 S8 | 77 | Apocrine metaplasia | U |
49101 | 56 | Fibroadenoma | ND |
136620 | 67 | Fibrocystic changes | P |
131665 | 64 | Fibrocystic changes | U |
85453 | 59 | Epithelial hyperplasia | U |
137340 S15 | 63 | Epithelial hyperplasia | P |
135990 S9 | 64 | Adenosis | U |
141007 S21 | 77 | Adenosis | U |
141300 S24 | 78 | Adenosis | U |
S14 136880 | 59 | Papilloma | U |
P=2/10=20% | |||
Group 2: Breast tumors | |||
1004172 (287767) | 50 | IDC, DCIS (GRADE III) | P |
1003361 (285220) | 68 | IDC | P |
1004363 (276283) | 58 | IDC (HIGH GRADE) | P |
1004783 (214003) | 73 | IDC, DCIS(GRADE III) | P |
1003356 (261845) | 57 | IDC (GRADE II) | U |
1000851 (265718) | 59 | IDC, DCIS | P |
1004041 (286233) | 37 | IDC (GRADE III) | P |
1003341 (279135) | 44 | IDC, DCIS (HIGH GRADE) | P |
1004582 (296190) | 52 | IDC (GRADE III) | P |
1004092 (284610) | 78 | IDC (GRADE III) | U |
1000826 (279038) | 73 | IDC (GRADE III) | P |
1002833 (268295) | 64 | IDC (GRADE III) | P |
1001581 (230160) | 64 | IDC (GRADE III) | P |
1001380 (243278) | 59 | IDC (GRADE II) | U |
1001168 (254401) | 51 | IDC (GRADE II) | P |
1001484 (239086) | 76 | IDC (GRADE I) | P |
1003731 (241220) | 51 | IDC (GRADE III) | P |
P= 14/17= 82.4% | |||
Group 3: Morphologically normal tissue adjacent to IC | |||
140569 C26 | 67 | IDC | P |
145565 | 62 | IDC, DCIS | U |
145564 | 74 | IDC | P |
133360 | 57 | U | |
141008 S22 | 55 | IDC, DCIS | U |
145813 | 53 | IDC | P |
147043 | 73 | IDC, DCIS | M |
145563 | 65 | IDC | P |
139128 S19 | 84 | IDC | P |
141299 S23 | 75 | IDC, DCIS | P |
154855 | 59 | IDC | U |
143061 | 73 | IDC and ILC | P |
157678 | 92 | ILC | P |
156105 | 73 | ILC | U |
P or M=9/14 = 64.3% |